FDA Approves Abrilada, Biosimilar to Humira, for Adults with Ankylosing Spondylitis and Other Disorders

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory diseases, including adults with ankylosing spondylitis. Pfizer, the company that developed Abrilada, expects the therapy to be available in the U.S. starting in 2023.